S-588410 + Placebo

Phase 2UNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-small- Cell Lung Cancer

Conditions

Non-small- Cell Lung Cancer

Trial Timeline

Mar 1, 2015 → Sep 1, 2021

About S-588410 + Placebo

S-588410 + Placebo is a phase 2 stage product being developed by Shionogi for Non-small- Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT02410369. Target conditions include Non-small- Cell Lung Cancer.

What happened to similar drugs?

7 of 20 similar drugs in Non-small- Cell Lung Cancer were approved

Approved (7) Terminated (6) Active (9)
Gefitinib + DocetaxelAstraZenecaApproved
PembrolizumabMerckApproved
zoledronic acidNovartisApproved
AtezolizumabRocheApproved
Erlotinib + ChemotherapyRocheApproved
LorlatinibPfizerApproved
Pemetrexed + ErlotinibHikma PharmaceuticalsApproved

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02410369Phase 2UNKNOWN

Competing Products

20 competing products in Non-small- Cell Lung Cancer

See all competitors